About Retinoid-inducible serine carboxypeptidase
Retinoid-inducible serine carboxypeptidase (SCPEP1) is a protein
from Homo sapiens identified by UniProt accession
Q9HB40, 452 residues long.
MolForge cross-references it against 0 known binders and
41 disease associations.
Target properties
| Protein name | Retinoid-inducible serine carboxypeptidase |
| UniProt accession | Q9HB40 |
| Gene | SCPEP1 |
| Organism | Homo sapiens |
| Length | 452 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (41)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.29
- joint disease · score 0.25
- leukocyte count · score 0.24
- mean platelet volume · score 0.18
- myeloid white cell count · score 0.15
- lymphocyte count · score 0.11
- snoring measurement · score 0.06
- hemoglobin measurement · score 0.03
- Sepsis · score 0.03
- chronic lymphocytic leukemia · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9HB40-F1 | alphafold | PREDICTED | 90.11 | — |
Amino-acid sequence (452 residues)
MELALRRSPV PRWLLLLPLL LGLNAGAVID WPTEEGKEVW DYVTVRKDAY MFWWLYYATN SCKNFSELPL VMWLQGGPGG SSTGFGNFEE IGPLDSDLKP RKTTWLQAAS LLFVDNPVGT GFSYVNGSGA YAKDLAMVAS DMMVLLKTFF SCHKEFQTVP FYIFSESYGG KMAAGIGLEL YKAIQRGTIK CNFAGVALGD SWISPVDSVL SWGPYLYSMS LLEDKGLAEV SKVAEQVLNA VNKGLYREAT ELWGKAEMII EQNTDGVNFY NILTKSTPTS TMESSLEFTQ SHLVCLCQRH VRHLQRDALS QLMNGPIRKK LKIIPEDQSW GGQATNVFVN MEEDFMKPVI SIVDELLEAG INVTVYNGQL DLIVDTMGQE AWVRKLKWPE LPKFSQLKWK ALYSDPKSLE TSAFVKSYKN LAFYWILKAG HMVPSDQGDM ALKMMRLVTQ QE
Explore Retinoid-inducible serine carboxypeptidase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets